New OWEAR Program Highlights Emerging De Facto Standards in Open-source Algorithms
The Open Wearables Initiative (OWEAR) announced a new program designed to identify and support open-source algorithms that are being adopted rapidly and may become de facto industry standards.
This OWEAR program uses the number and quality of references to “crowdsource” the identification of potential de facto standards. Once a potential standard is identified, OWEAR will create and maintain a searchable catalog that displays key information about the studies in which the algorithm has been employed, including the therapeutic area, population(s) studied, and number of participants.
OWEAR plans to create a new catalog for each open-source algorithm used in a wearable sensor or other connected health technology that generates more than 25 published papers and meets other quality metrics. The reference-count criterion indicates that the algorithm has garnered significant industry adoption. Shimmer Research, Inc. has agreed to donate the staff time to create and maintain these OWEAR catalogs.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
